首页> 美国卫生研究院文献>BMC Blood Disorders >Hematopoietic chimerism after allogeneic stem cell transplantation: a comparison of quantitative analysis by automated DNA sizing and fluorescent in situ hybridization
【2h】

Hematopoietic chimerism after allogeneic stem cell transplantation: a comparison of quantitative analysis by automated DNA sizing and fluorescent in situ hybridization

机译:同种异体干细胞移植后的造血嵌合:自动DNA大小和荧光原位杂交定量分析的比较

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundAllogeneic hematopoietic stem cell transplantation (allo-HSCT) is performed mainly in patients with high-risk or advanced hematologic malignancies and congenital or acquired aplastic anemias. In the context of the significant risk of graft failure after allo-HSCT from alternative donors and the risk of relapse in recipients transplanted for malignancy, the precise monitoring of posttransplant hematopoietic chimerism is of utmost interest. Useful molecular methods for chimerism quantification after allogeneic transplantation, aimed at distinguishing precisely between donor's and recipient's cells, are PCR-based analyses of polymorphic DNA markers. Such analyses can be performed regardless of donor's and recipient's sex. Additionally, in patients after sex-mismatched allo-HSCT, fluorescent in situ hybridization (FISH) can be applied.
机译:背景异基因造血干细胞移植(allo-HSCT)主要在高危或晚期血液系统恶性肿瘤,先天性或获得性再生障碍性贫血的患者中进行。考虑到异体造血干细胞移植后移植供体发生移植失败的巨大风险以及因恶性而移植的受体发生复发的风险,对移植后造血嵌合的精确监测至关重要。异源移植后用于定量嵌合体的有用分子方法是基于PCR的多态性DNA标记分析,旨在精确区分供体和受体细胞。可以进行这样的分析,而与捐赠者和接受者的性别无关。另外,在性别不匹配的异基因-HSCT后的患者中,可以应用荧光原位杂交(FISH)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号